Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients

Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials

(2016) Ronald F. van Vollenhoven et al.   Arthritis & Rheumatology

Upcoming biological therapies in systemic lupus erythematosus

(2015) Savino Sciascia et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices

(2015) J. S. Hui-Yuen et al.   JOURNAL OF RHEUMATOLOGY

Treatment Algorithms in Systemic Lupus Erythematosus

(2015) Chayawee Muangchan et al.   ARTHRITIS CARE & RESEARCH

Belimumab in systemic lupus erythematosus: a perspective review

(2015) Joyce S. Hui-Yuen et al.   Therapeutic Advances in Musculoskeletal Disease

Real life experience on the effect of Belimumab in patients with active systemic lupus

(2015) Morton Scheinberg et al.   SpringerPlus

The efficacy of novel B cell biologics as the future of SLE treatment: A review

(2014) Ameer Kamal et al.   AUTOIMMUNITY REVIEWS

The BAFF/APRIL system in SLE pathogenesis

(2014) Fabien B. Vincent et al.   Nature Reviews Rheumatology

Post-marketing Experiences with Belimumab in the Treatment of SLE Patients

(2014) Anca D. Askanase et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

A23: Favorable Response to Belimumab in Childhood-Onset Systemic Lupus Erythematosus

(2014) Joyce S Hui-Yuen et al.   Arthritis & Rheumatology

Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review

(2014) Hon Yuen et al.   Therapeutics and Clinical Risk Management

Biologics in SLE: Towards new approaches

(2013) Ronald F. van Vollenhoven et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

(2013) E. M. Ginzler et al.   JOURNAL OF RHEUMATOLOGY

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

(2012) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE

(2012) MA Dooley et al.   LUPUS

Belimumab Is Approved by the FDA: What More Do We Need to Know to Optimize Decision Making?

(2012) Diane Lewis Horowitz et al.   Current Rheumatology Reports

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

SLEDAI-2K for a 30-day window

(2009) Z. Touma et al.   LUPUS

Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, São Paulo, Brazil

(2008) Morton Scheinberg et al.   CLINICAL RHEUMATOLOGY